Sign in Subscribe
Genetic research

Next-Generation Sequencing Reveals Clinical Features and Prognosis of Gene Mutations in Chinese Children with T-Cell Acute Lymphoblastic Leukemia

Strategic Insights

— 2 min read

Researchers at the Children's Hospital of Soochow University in Suzhou, People's Republic of China, have conducted a study on the clinical features and prognosis of gene mutations in pediatric patients with T-cell acute lymphoblastic leukemia (T-ALL). The study, published in Frontiers in Oncology, analyzed data from 144 pediatric patients with T-ALL and used next-generation sequencing (NGS) to identify recurrent mutated genes. The researchers found that the 5-year overall survival (OS) for pediatric T-ALL exceeds 80% under current treatment strategies, but some patients experience treatment failure. The study highlights the importance of NGS in molecular classification, risk stratification, and prognosis.

Key Takeaways:

  • The 5-year overall survival (OS) for pediatric T-cell acute lymphoblastic leukemia (T-ALL) exceeds 80% under current treatment strategies.
  • Next-generation sequencing (NGS) identified recurrent mutated genes in T-ALL, including mutations in (58.3%), (19.4%), and (17.4%).
  • Patients with higher mutation loads had a lower proportion of D15 minimal residual disease (0.01%) and better survival than those with a lower load.
  • The study reported the gene mutation spectrum of Chinese pediatric T-ALL, emphasizing the role of NGS in molecular classification, risk stratification, and prognosis.
  • The variant allele frequency of mutations played a crucial role in the treatment response and prognosis of childhood T-ALL.
  • The study enrolled 144 pediatric patients with T-ALL at the Children's Hospital of Soochow University, with a median age of 8.9 years.
  • Chi-square or Fisher's exact tests were used for categorical variables, and Kaplan-Meier and log-rank tests analyzed the survival rates of patients.
  • The research concluded that NGS is essential for understanding the molecular characteristics of T-ALL and improving treatment outcomes.

Statistics:

  • 144 pediatric patients with T-ALL were enrolled in the study, with a median age of 8.9 years.
  • The 5-year overall survival (OS) for pediatric T-ALL exceeds 80% under current treatment strategies.
  • 50 gene mutations detected had a mutation frequency of 1%.
  • 58.3% of patients had mutations in, 19.4% in, and 17.4% in.
  • Patients with higher mutation loads had a lower proportion of D15 minimal residual disease (0.01%) and better survival than those with a lower load.

Sources:

  • Frontiers in Oncology, 2025;15:1666527
  • NewsRx. Studies from Children's Hospital of Soochow University in the Area of Acute Lymphoblastic Leukemia Reported (Next-generation sequencing reveals clinical features and prognosis of gene mutations in Chinese children with T-cell acute ...). Hematology Week. October 27, 2025; p 686.

Read more